Drugs / Marrow infiltrating lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04677361 | Oct 2021 → Oct 2023 | non-small cell lung carcinoma, small cell lung carcinoma | Fox Chase Cancer Center | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Marrow infiltrating lymphocytes | “Marrow infiltrating lymphocytes (MILs™) are a novel method of adoptive cell therapy that provide an activated, polyclonal population of autologous tumor-specific T cells...” NCT04677361 ↗ |
| Known as | MILs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677361 ↗ |
| Modality | Cell therapy | “adoptive cell therapy” NCT04677361 ↗ |
| Route | Other | “The MILs™ must be administered via a central catheter” NCT04677361 ↗ |